Rasayana Therapeutics

Executive Summary

Rasayana Therapeutics is a clinical-stage biotechnology company pioneering a novel approach to treating chronic inflammatory diseases by targeting their root cause in the gut. Its lead program, an oral recombinant form of Intestinal Alkaline Phosphatase (IAP), aims to restore immune homeostasis and gut barrier integrity, addressing upstream drivers of systemic inflammation such as inflammatory bowel disease and potentially other autoimmune conditions. The company's oral biologic platform offers significant advantages over injectable biologics, including improved patient compliance and reduced systemic side effects. With a Phase 2 trial underway, Rasayana is positioned to demonstrate proof-of-concept in 2026, which could validate its gut-centric therapeutic paradigm and unlock substantial value. The platform's versatility may enable expansion into multiple inflammatory indications, providing multiple shots on goal.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data readout for lead IAP program55% success
• Q4 2026Initiation of Phase 3 planning or regulatory guidance40% success
• TBDPotential partnership or licensing deal for non-core indications30% success